CLASS II ONGOING Drug recall · Reported 20 Jan 2021 · FDA Enforcement Report

Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg recalled

Nostrum Laboratories is recalling Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg per, distributed nationwide in the US. The recall was initiated on 4 Jan 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesMET200501 07/2022
Quantity recalled6958 Bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0227-2021
FDA event ID
87080
Recalling firm
Nostrum Laboratories, Kansas City, MO
Classification
Class II
Status
Ongoing
Recall initiated
4 Jan 2021
FDA classified
14 Jan 2021
Reported
20 Jan 2021
Type
Voluntary: Firm initiated
Customers notified by
Press Release
Reason category
Nitrosamine Impurity

Timeline

4 Jan 2021Recall initiated by company
14 Jan 2021Classified by FDA+10 days
20 Jan 2021Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 tablets per bottle, Rx Only, Manufactured by: Nostrum Laboratories, Inc., Kansas City, MO 64120, NDC: 29033-056-01

Where it was distributed

Nationwide

Nationwide

Questions about this recall

Is Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg per recalled?

Yes. Nostrum Laboratories recalled Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg per on 4 Jan 2021. The recall is Class II and its status is Ongoing. Recall number D-0227-2021.

Why was it recalled?

CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Which lots are affected?

MET200501 07/2022

Where was it sold?

Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Nostrum Laboratories

All 8

Other Metformin recalls

All 57